Pharmacologic mechanisms of crystal meth
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Crystal meth is a form of the stimulant drug methamphetamine that, when smoked, can rapidly achieve high concentrations in the brain. Methamphetamine causes the release of the neurotransmitters dopamine, norepinephrine and serotonin and activates the cardiovascular and central nervous systems. The levels of dopamine are low in the brain of some drug users, but whether this represents neuronal loss is uncertain. The areas of the brain involved in methamphetamine addiction are unknown but probably include the dopamine-rich striatum and regions that interact with the striatum. There is no medication approved for the treatment of relapses of methamphetamine addiction; however, potential therapeutic agents targeted to dopamine and nondopamine (e.g., opioid) systems are in clinical testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733 · cited 1×
“Previously, dopamine in the ventral portion of the striatum (Figure 2) was considered to be the “pleasure” neurotransmitter involved in the action of all abused drugs.(17,21,22) However, clinical findings suggest that drugs that block the dopamine receptor do not block methamphetamine “liking.”
BackgroundDeep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059
Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits
Salamone, J. D., Correa, M., Farrar, A., & Mingote, S. M. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0668-9 · Cited by 1,000
Addiction: A Disease of Learning and Memory
Hyman, S. E. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1414 · Cited by 980
Robinson, T. E., & Kolb, B. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-21-08491.1997 · Cited by 704 · cited 1×
“, in dendritic spine density) that make the addiction resistant to therapeutic intervention.(32)”
BackgroundNew concepts in cocaine addiction: The dopamine depletion hypothesis
Dackis, C. A., & Gold, M. S. (1985) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(85)90022-3 · Cited by 607 · cited 1×
“Previously, dopamine in the ventral portion of the striatum (Figure 2) was considered to be the “pleasure” neurotransmitter involved in the action of all abused drugs.(17,21,22) However, clinical findings suggest that drugs that block the dopamine receptor do not block methamphetamine “liking.”
BackgroundMichelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599
Roberts, D. C. S., & Koob, G. F. (1982) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(82)90469-5 · Cited by 448 · cited 1×
“Previously, dopamine in the ventral portion of the striatum (Figure 2) was considered to be the “pleasure” neurotransmitter involved in the action of all abused drugs.(17,21,22) However, clinical findings suggest that drugs that block the dopamine receptor do not block methamphetamine “liking.”
BackgroundRollema, H., Coe, J. W., Chambers, L. K., Hurst, R. S., Stahl, S. M., & Williams, K. E. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.05.003 · Cited by 400 · cited 1×
“More generally, the efficacy of varenicline for tobacco cessation provides hope that a therapeutic approach that uses a partial agonist (a single compound having both agonist and antagonist properties) might be helpful in treating other addictions.(34) It has also been proposed that “drug substitution therapy” (low do…”
BackgroundThe epidemiology of methamphetamine use and harm in Australia
DEGENHARDT, L., ROXBURGH, A., BLACK, E., BRUNO, R., CAMPBELL, G., KINNER, S., & FETHERSTON, J. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801950572 · Cited by 134
Cited by
Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings
Panenka, W. J., Procyshyn, R. M., Lecomte, T., MacEwan, G. W., Flynn, S. W., Honer, W. G., & Barr, A. M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.11.016 · Cited by 432
“In 1971, MA was restricted y US law, although oral MA (Ovation Pharmaceuticals) continues o be used today in the US as a second-line treatment for a numer of medical conditions, including attention deficit hyperactivity isorder (ADHD) and refractory obesity (Kish, 2008).”
BackgroundCallaghan, R. C., Cunningham, J. K., Sykes, J., & Kish, S. J. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.06.013 · Cited by 272
Self-citation
Metadata
- Authors
- Kish, S. J.
- Venue
- Canadian Medical Association Journal
- Publisher
- CMA Joule Inc.
- Published
- 2008-06-17
- Volume
- 178
- Issue
- 13
- Pages
- 1679-1682
- ISSN
- 0820-3946 (ISSN-L)
- 1488-2329
- OpenAlex
- W2162097305
- Cited by
- 207
- References
- 10
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.